(9S)-3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one

• ChemBase编号: 72792
• 分子式: C23H27FN4O3
• 平均质量: 426.4838832
• 单一同位素质量: 426.20671896
• SMILES: c1(c(c(=O)n2c(n1)[C@H](CCC2)O)CCN1CCC(CC1)c1c2c(on1)cc(cc2)F)C
• Canonical SMILES: Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCC[C@@H]2O
• InChI: InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3/t19-/m0/s1
• InChIKey: PMXMIIMHBWHSKN-IBGZPJMESA-N

名称和登记号

名称

• IUPAC标准名: (9S)-3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
• IUPAC传统名: (9S)-3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
• 别名: (9S)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; (-)-9-Hydroxyrisperidone; 9-(S)-Paliperidone; (S)-9-Hydroxy Risperidone; Invega; INVEGA Sustenna; 9-hydroxyrisperidone; Paliperidone

登记号

• CAS号: 144598-75-4; 147663-01-2
• PubChem SID: 162037713
• PubChem CID: 9823781

理论计算性质

• Acid pKa: 13.742356
• 质子受体: 5
• 质子供体: 1
• LogD (pH = 5.5): -1.3088015
• LogD (pH = 7.4): 0.37811172
• Log P: 1.7565552
• 摩尔折射率: 116.0414 cm^3
• 极化性: 44.54549 Å^3
• 极化表面积: 82.17 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

分子性质

安全信息

• 保存条件: -20°C

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S1724

Research Area: Neurological Disease
Biological Activity:
Paliperidone(Invega) is an atypical antipsychotic. Chemically, paliperidone is the primary active metabolite of the older atypical antipsychotic risperidone. It is indicated for the acute and maintenance treatment of schizophrenia. [1]

Toronto Research Chemicals - H953360

The S-enantiomer metabolite of Risperidone, a combined serotonin (5-HT2) and dopamine (D2) receptor antagonist.

参考文献

• http://en.wikipedia.org/wiki/Paliperidone
• Tiberghien, F., et al.: Anticancer Drugs, 7, 568 (1996)
• Kansy, M., et al.: J. Med. Chem., 41, 1007 (1996)
• Kerns, E., et al.: J. Pharm. Sci., 90, 1838 (1996)
• Kerr, K., et al.: J. Biol. Chem., 276, 8657 (1996)
• Doran, A., et al.: Drug Metab. Dispos., 33,